Search research articles
Contact Us
Filters
Showing results (641-650 of 684) with videos related to
Page
of 69
Sort By:
Cancer Discovery
|
April 25, 2019
PARP Inhibitor Efficacy Depends on CD8<sup>+</sup> T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Constantia Pantelidou, Olmo Sonzogni, Mateus De Oliveria Taveira, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 31, 2008
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, et al.
Oncogene
|
December 17, 2025
MDC1 counteracts replication fork reversal and mediates chemosensitivity in BRCA1/2-deficient tumors
Hülya Dogan, Martin Liptay, Joana S Barbosa, et al.
Cancer Discovery
|
October 30, 2012
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors
Janneke E Jaspers, Ariena Kersbergen, Ute Boon, et al.
Parkinsonism & Related Disorders
|
April 1, 2014
Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease
A J H Moonen, A Wijers, A F G Leentjens, et al.
Cancer Research Communications
|
December 5, 2022
Loss of the volume-regulated anion channel components LRRC8A and LRRC8D limits platinum drug efficacy
Carmen A Widmer, Ismar Klebic, Natalya Domanitskaya, et al.
Cancer Research
|
August 24, 2016
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
Lenka Oplustil O'Connor, Stuart L Rulten, Aaron N Cranston, et al.
Biorxiv : the Preprint Server for Biology
|
August 2, 2024
Deep Learning-based Modeling for Preclinical Drug Safety Assessment
Guillaume Jaume, Simone de Brot, Andrew H Song, et al.
British Journal of Cancer
|
June 12, 2024
Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1)
S Lot Aronson, Cédric Walker, Bram Thijssen, et al.
The EMBO Journal
|
November 5, 2015
Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs
Rosa Planells-Cases, Darius Lutter, Charlotte Guyader, et al.
Page
of 69
Search research articles
Search
Showing results (641-650 of 684) with videos related to
Sort By:
Page
of 69
Cancer Discovery
|
April 25, 2019
PARP Inhibitor Efficacy Depends on CD8<sup>+</sup> T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Constantia Pantelidou, Olmo Sonzogni, Mateus De Oliveria Taveira, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 31, 2008
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, et al.
Oncogene
|
December 17, 2025
MDC1 counteracts replication fork reversal and mediates chemosensitivity in BRCA1/2-deficient tumors
Hülya Dogan, Martin Liptay, Joana S Barbosa, et al.
Cancer Discovery
|
October 30, 2012
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors
Janneke E Jaspers, Ariena Kersbergen, Ute Boon, et al.
Parkinsonism & Related Disorders
|
April 1, 2014
Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease
A J H Moonen, A Wijers, A F G Leentjens, et al.
Cancer Research Communications
|
December 5, 2022
Loss of the volume-regulated anion channel components LRRC8A and LRRC8D limits platinum drug efficacy
Carmen A Widmer, Ismar Klebic, Natalya Domanitskaya, et al.
Cancer Research
|
August 24, 2016
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
Lenka Oplustil O'Connor, Stuart L Rulten, Aaron N Cranston, et al.
Biorxiv : the Preprint Server for Biology
|
August 2, 2024
Deep Learning-based Modeling for Preclinical Drug Safety Assessment
Guillaume Jaume, Simone de Brot, Andrew H Song, et al.
British Journal of Cancer
|
June 12, 2024
Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1)
S Lot Aronson, Cédric Walker, Bram Thijssen, et al.
The EMBO Journal
|
November 5, 2015
Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs
Rosa Planells-Cases, Darius Lutter, Charlotte Guyader, et al.
Page
of 69